Why It Matters
WW International’s pivot to lobbying on GLP-1 medication coverage signals a fundamental business transformation with substantial policy implications. The company’s hiring of Akin Gump Strauss Hauer & Feld LLP represents a major strategic shift from its previous general health policy approach to sophisticated pharmaceutical advocacy.
Passage of the Treat and Reduce Obesity Act of 2025 would directly enable WW’s new integrated medical-behavioral model by mandating Medicare and Medicaid coverage for anti-obesity medications. This legislative victory would legitimize the entire telehealth weight-loss sector and potentially unlock billions in new coverage expansions.
By the Numbers
WW International Inc. has lobbied Congress for over two decades, filing 72 disclosures and spending more than $2.8 million since 2003. The company previously worked with smaller firms on general wellness issues.
WW now retained Akin Gump Strauss Hauer & Feld LLP, registering four lobbyists for pharmaceutical policy work.
WW’s lobbying team is exceptionally well-positioned. Shawn Maree Bishop served as Chief Adviser for Health on the Senate Finance Committee—the panel controlling Medicare policy. Anna K. Abram directed health policy for the Senate HELP Committee, which oversees FDA regulation.
The Agenda
The company is focused on securing passage of the Treat and Reduce Obesity Act of 2025, which would mandate Medicare coverage for GLP-1 medications and expand behavioral therapy coverage. WW’s new business model integrates telehealth drug prescriptions with traditional weight-loss programs, making this legislation directly relevant to its bottom line.
WW joins pharmaceutical giants Novo Nordisk Inc. and Eli Lilly & Co. in advocating for expanded coverage, alongside healthcare groups like the Health Equity Coalition for Chronic Disease.
Broader Context
Congress is actively debating obesity treatment policy at a pivotal moment. The Treat and Reduce Obesity Act of 2025 would repeal a 20-year Medicare ban on covering weight-loss medications, with bipartisan support from Rep. Mike Kelly (R-PA) and Sen. Ben Ray Luján (D-NM).
WW’s shift toward GLP-1 medications through telehealth aligns with legislative opportunities in a rapidly expanding market projected to grow at 22.7% annually through 2032. However, the company faces significant headwinds from cost-focused lawmakers like Sen. Bernie Sanders (I-VT) and intense competition from pharmaceutical giants already heavily lobbying Congress.
Between The Lines
The Treat and Reduce Obesity Act enjoys bipartisan support from Rep. Raul Ruiz (D-CA), Sen. Bill Cassidy (R-LA), and others. Recent congressional hearings on Medicare Advantage and HHS budget priorities have emphasized chronic disease management as a policy priority.
However, significant opposition centers on drug costs. Sen. Sanders and Sen. Tammy Baldwin (D-WI) have praised Medicare price negotiations for GLP-1s, framing coverage expansion as secondary to affordability concerns.
Competitive Landscape
WW enters a crowded lobbying ecosystem dominated by Novo Nordisk and Eli Lilly, the leading GLP-1 manufacturers who have dramatically scaled lobbying efforts. A diverse coalition including the American Gastroenterological Association and Gerontological Society of America also supports the legislation.
The telehealth sector presents different competitive dynamics, with companies like Hims also lobbying heavily on obesity medication access. WW faces price-focused congressional opposition that prioritizes cost containment over access expansion.
The Bottom Line
WW International has significantly upgraded its lobbying firepower by hiring Akin Gump, marking a strategic shift from general wellness advocacy to pharmaceutical market access. This reflects WW’s business transformation into a medical-behavioral model combining telehealth GLP-1 prescriptions with traditional weight-loss coaching.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article